Gilead Sciences, Inc. (FRA:GIS)
Germany · Delayed Price · Currency is EUR | Market Cap | 131.60B |
| Revenue (ttm) | 24.79B |
| Net Income (ttm) | 6.91B |
| Shares Out | n/a |
| EPS (ttm) | 5.47 |
| PE Ratio | 19.04 |
| Forward PE | 14.89 |
| Dividend | 2.76 (2.60%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 380 |
| Average Volume | 323 |
| Open | 103.46 |
| Previous Close | 104.02 |
| Day's Range | 102.76 - 106.20 |
| 52-Week Range | 82.61 - 111.04 |
| Beta | n/a |
| RSI | 53.51 |
| Earnings Date | Feb 10, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal
President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medicaid program on Friday, bringing U.S. cost...
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much ...
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
Officials pledge ‘massive savings’ as companies agree to offer drugs at prices equal to those in other wealthy nations Donald Trump and nine major pharmaceutical companies on Friday announced deals th...
Gilead (GILD) Strikes Deal to Cut Drug Costs With U.S. Government
Gilead (GILD) Strikes Deal to Cut Drug Costs With U.S. Government
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company's ...
GILD's Lenacapavir Gains UK Approval for HIV-1 Prevention
GILD's Lenacapavir Gains UK Approval for HIV-1 Prevention
Trump to announce new drug-pricing deals later today
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Will GILD's Strong HIV Portfolio Reap Rewards in 2026?
GILD???s HIV franchise gains momentum as twice-yearly PrEP Yeztugo wins FDA approval and late-stage data back a new single-tablet regimen.
AbbVie, Bristol Myers, Merck among latest to announce U.S. drug pricing deals: Reuters
AbbVie (ABBV), Bristol Myers Squibb (BMY), Gilead (GILD), and Merck (MRK) are set to annouce U.S. drug pricing deals. Read more here.
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective ...
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
Gilead Sciences (GILD) closed the most recent trading day at $121.36, moving +2.17% from the previous trading session.
Insider Sell: Johanna Mercier Sells 3,000 Shares of Gilead Sciences Inc (GILD)
Insider Sell: Johanna Mercier Sells 3,000 Shares of Gilead Sciences Inc (GILD)
XLV, AMGN, GILD, MDT: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where we...
Gilead Sciences Reports Positive Phase 3 ARTISTRY-2 HIV Trial Results
(RTTNews) - Gilead Sciences (GILD) on Monday reported positive topline results from the Phase 3 ARTISTRY-2 trial.
Gilead Sciences (GILD) Achieves Phase 3 Trial Success with Yeztugo
Gilead Sciences (GILD) Achieves Phase 3 Trial Success with Yeztugo
RCUS Stock Down on Decision to Discontinue GILD Partnered Study
Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.
Gilead (GILD) Hits Key Milestone with ARTISTRY-2 HIV Treatment Trial
Gilead (GILD) Hits Key Milestone with ARTISTRY-2 HIV Treatment Trial
Gilead's experimental HIV treatment meets main goal in late-stage trial
Gilead Sciences said on Monday its experimental HIV treatment met the main goal in a late-stage trial.
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment re...
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Arcus Biosciences, Inc . (NYSE: RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc . (NASDAQ: GILD), due to futilit...
GILEAD SCIENCES (GILD): Morgan Stanley Raises Price Target, Maintains Overweight Rating | GILD ...
GILEAD SCIENCES (GILD): Morgan Stanley Raises Price Target, Maintains Overweight Rating | GILD Stock News
GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficacy
GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficacy